TP53 and leukemia: Although our preliminary tests in HL60VCRluc-transplant mouse models showed that MMRi62 inhibited the HL60VCRluc burden in vivo but failed to prolong survival at the current formulation/route/schedule (Figure S6B), MMRi62 optimization may lead to the eventual development of a better MDM4 degrader that will be useful for refractory p53-deficient leukemia patients.